Amylyx Pharmaceuticals (AMLX) Expected to Announce Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) is expected to be announcing its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

Amylyx Pharmaceuticals Trading Down 6.3 %

Shares of Amylyx Pharmaceuticals stock traded down $0.22 during trading on Friday, hitting $3.30. 492,206 shares of the stock were exchanged, compared to its average volume of 723,815. The company has a fifty day moving average price of $3.69 and a 200-day moving average price of $3.78. The stock has a market capitalization of $226.22 million, a price-to-earnings ratio of -0.86 and a beta of -0.54. Amylyx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $19.95.

Insider Activity at Amylyx Pharmaceuticals

In other news, CEO Justin B. Klee sold 7,471 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $4.04, for a total value of $30,182.84. Following the sale, the chief executive officer now directly owns 3,176,788 shares in the company, valued at approximately $12,834,223.52. This trade represents a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Joshua B. Cohen sold 11,851 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $3.47, for a total transaction of $41,122.97. Following the sale, the chief executive officer now directly owns 3,201,247 shares in the company, valued at $11,108,327.09. This trade represents a 0.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,000 shares of company stock valued at $84,142 over the last three months. 11.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on AMLX shares. Baird R W raised Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Monday, November 18th. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a report on Thursday, December 5th. Finally, Robert W. Baird upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and upped their price target for the company from $3.00 to $11.00 in a research note on Monday, November 18th. Five analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $7.33.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.